Biotech Values

[DewDiligence]

FDA approves “convalescent plasma” for COVID-19 treatment—on a case-by-case basis:

https://www.wsj.com/articles/fda-approves-plasma-treatment-for-coronavirus-under-certain-circumstances-11585090669

The Food and Drug Administration has begun to allow doctors to treat some patients with the blood plasma of patients who have recovered from the coronavirus-caused Covid-19 disease.

The treatment must be approved on a case-by-case basis, and patients must meet certain conditions, the FDA said.

The treatment is considered investigational, and based on the possibility that the so-called convalescent plasma—a portion of whole blood from recovered victims—contains antibodies to the virus that may be effective against the infection.

The limited supply is the biggest drawback of this approach.